Immune checkpoint inhibitors for multiple myeloma immunotherapy

被引:13
|
作者
Liu, Zhaoyun [1 ]
Xu, Xintong [1 ]
Liu, Hui [1 ]
Zhao, Xianghong [1 ]
Yang, Chun [1 ]
Fu, Rong [1 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin 300052, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune checkpoint; CTLA-4; TIGIT; Multiple myeloma; treatment strategy; T-LYMPHOCYTE ATTENUATOR; KIR ANTIBODY IPH2101; PHASE-I TRIAL; PD-1; BLOCKADE; DARATUMUMAB MONOTHERAPY; ANTITUMOR IMMUNITY; B-LYMPHOCYTE; PLASMA-CELLS; EXPRESSION; CANCER;
D O I
10.1186/s40164-023-00456-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively modulate the immune system and are closely associated with immune escape. Immune checkpoint-related therapy has attracted much attention and research in MM. However, the efficacy of those therapies need further improvements. There need more thoughts about the immune checkpoint to translate their use in clinical work. In our review, we aggregated the currently known immune checkpoints and their corresponding ligands, further more we propose various ways of potential translation applying treatment based on immune checkpoints for MM patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors for multiple myeloma immunotherapy
    Zhaoyun Liu
    Xintong Xu
    Hui Liu
    Xianghong Zhao
    Chun Yang
    Rong Fu
    Experimental Hematology & Oncology, 12
  • [2] Immune checkpoint inhibitors in multiple myeloma: A review of the literature
    Caserta, Santino
    Innao, Vanessa
    Musolino, Caterina
    Allegra, Alessandro
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (10)
  • [3] Immune checkpoint inhibitors in cancer immunotherapy
    Himmel, Megan E.
    Saibil, Samuel D.
    Saltman, Alexandra P.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (24) : E651 - E651
  • [4] Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients
    Castella, Barbara
    Foglietta, Myriam
    Sciancalepore, Patrizia
    Tripoli, Ezio
    Boccadoro, Mario
    Massaia, Massimo
    BLOOD, 2016, 128 (22)
  • [5] Cancer immunotherapy beyond immune checkpoint inhibitors
    Marin-Acevedo, Julian A.
    Soyano, Aixa E.
    Dholaria, Bhagirathbhai
    Knutson, Keith L.
    Lou, Yanyan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [6] Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy
    Guo, Qiao
    5TH ANNUAL INTERNATIONAL CONFERENCE ON MATERIAL SCIENCE AND ENVIRONMENTAL ENGINEERING (MSEE2017), 2018, 301
  • [7] Cancer immunotherapy beyond immune checkpoint inhibitors
    Julian A. Marin-Acevedo
    Aixa E. Soyano
    Bhagirathbhai Dholaria
    Keith L. Knutson
    Yanyan Lou
    Journal of Hematology & Oncology, 11
  • [8] Immune checkpoint inhibitors: The linchpins of modern immunotherapy
    Wilky, Breelyn A.
    IMMUNOLOGICAL REVIEWS, 2019, 290 (01) : 6 - 23
  • [9] The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma
    Chakrabarti, Ritu
    Siegel, David
    Biran, Noa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (02): : 96 - 108
  • [10] Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
    Priyatharcini Kejamurthy
    K. T. Ramya Devi
    Medical Oncology, 41